Ruxolitinib
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
- Ruxolitinib
- Ruxolitinib: From Myeloproliferative Neoplasms to Infection-Associated Hemophagocytic Lymphohistiocytosis (HLH)
Using judgment on evidence selection: TxGNN’s top-ranked candidate (uterine PEComa, score 99.73%) has zero supporting trials or literature and mechanistically conflicts with ruxolitinib’s JAK1/2 pathway (PEComa is TSC/mTOR-driven). I’m reporting instead on the highest-scoring candidate with actual evidentiary support — infection-associated HLH — and flagging this deviation transparently below.
Ruxolitinib: From Myeloproliferative Neoplasms to Infection-Associated Hemophagocytic Lymphohistiocytosis (HLH)
One-Sentence Summary
Ruxolitinib is a JAK1/2 inhibitor; the current evidence pack does not contain its original approved indication or mechanism-of-action text (data gap), but it is publicly known as a treatment for myelofibrosis and related myeloproliferative neoplasms. Among 10 TxGNN-predicted indications for this drug, the model assigns a near-identical top score to infection-associated hemophagocytic lymphohistiocytosis (HLH) — the only candidate among the top 10 backed by an actual randomized trial and a substantial literature base (1 clinical trial cluster, 20 publications), while the single highest-scored prediction (uterine PEComa) has no supporting evidence at all.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not provided in evidence pack (data gap); publicly known use includes myelofibrosis/myeloproliferative neoplasms |
| Predicted New Indication | Infection-associated Hemophagocytic Lymphohistiocytosis (HLH) |
| TxGNN Prediction Score | 99.32% (global model rank 10,805) |
| Evidence Level | L2 |
| Taiwan Market Status | Not marketed (Not marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available in the evidence pack (data gap DG002). Based on publicly known pharmacology, ruxolitinib is a JAK1/2 tyrosine kinase inhibitor that blocks intracellular signaling downstream of pro-inflammatory cytokines, including interferon-gamma (IFN-γ) and IL-6.
Infection-associated HLH is a cytokine-storm syndrome driven by excessive IFN-γ/IL-6 signaling transmitted through the JAK-STAT pathway. Because ruxolitinib directly inhibits this pathway, the mechanistic link to HLH is strong and specific — unlike most of the other TxGNN top-10 predictions for this drug (e.g., PEComa, lymphangioleiomyomatosis, familial rhabdoid tumor), which are driven by unrelated pathways (TSC1/TSC2-mTOR, SMARCB1 loss) and carry no supporting mechanism or clinical evidence.
This rationale is corroborated by murine mechanistic studies (PMID 31015190, 32530039) showing ruxolitinib dampens IFN-γ-driven T-cell hyperactivation in HLH models, and by a 2022 critical care consensus guideline (PMID 34605776) that references JAK inhibition as part of HLH management in critically ill patients.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04424056 | Phase 3 | Unknown | 216 | Randomized trial comparing Anakinra, Tocilizumab alone or combined with Ruxolitinib for severe COVID-19-associated hyperinflammatory disease (stage 2b/3); status unconfirmed (not verified as completed), limiting upgrade to L1 |
| NCT07424222 | Phase 1 | Not yet recruiting | 16 | Pilot safety/efficacy study of ruxolitinib in immune-effector-cell–associated HLH-like syndrome (IEC-HS) after CAR-T therapy |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 34605776 | 2022 | Review/Guideline | Critical Care Medicine | Consensus-based guideline for recognition, diagnosis, and management of HLH in critically ill children and adults |
| 31943120 | 2020 | Review | QJM | Adult HLH review covering diagnosis and treatment landscape |
| 35344583 | 2022 | Prospective Cohort | Blood | Ruxolitinib as first-line, response-stratified therapy in pediatric HLH (registered study) |
| 32732367 | 2021 | Pilot/Prospective | Haematologica | Front-line ruxolitinib in 12 children with secondary HLH |
| 40665481 | 2025 | Cohort | British Journal of Haematology | Ruxolitinib-based regimen vs. HLH-94 chemotherapy in 53 pediatric EBV-HLH patients vs. 42 controls |
| 37787838 | 2023 | Cohort/Case series | Annals of Hematology | Sintilimab + ruxolitinib as compassionate therapy in 12 adults with EBV-HLH |
| 38984023 | 2024 | Case series | Translational Pediatrics | Ruxolitinib salvage therapy for refractory adenovirus-associated HLH post-HSCT |
| 31015190 | 2019 | Mechanistic | Blood | Mechanism of ruxolitinib action in murine HLH models — inhibits IFN-γ downstream signaling |
| 32530039 | 2020 | Mechanistic | Blood | JAK/STAT inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation |
| 34353999 | 2021 | Review | Current Opinion in Critical Care | JAK inhibitors (including ruxolitinib) for hospitalized COVID-19-associated hyperinflammation |
Taiwan Market Information
Ruxolitinib currently holds no registration in the Taiwan regulatory dataset (market_status: Not marketed, 0 licenses on file).
Safety Considerations
Drug Interactions (338 total interactions on file; selected Major-level examples):
- Clarithromycin — Major
- Cobicistat — Major
- Deferasirox — Major
- Deferiprone — Major
- Ibritumomab tiuxetan — Major
- Tositumomab / Tositumomab (I-131) — Major
- Samarium (153Sm) lexidronam — Major
Detailed key warnings and contraindications are not available in the current evidence pack (data gap DG001 — TFDA label not yet retrieved). Please refer to the package insert for full safety information once obtained.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Infection-associated HLH has a direct, well-characterized mechanistic link to ruxolitinib’s JAK1/2 inhibition, and is supported by consensus guidelines, multiple cohort/case-series studies, and mechanistic trial data (L2/S2). However, the one directly relevant Phase 3 RCT (NCT04424056) has unconfirmed completion status, and the drug is not currently marketed in Taiwan.
To proceed, the following is needed:
- TFDA label data (warnings/contraindications) — currently blocking (DG001)
- Confirmed mechanism-of-action documentation (DG002)
- Follow-up on NCT04424056 completion/publication status
- Taiwan market-access assessment given zero current registrations
- Evaluation of the 8 other TxGNN-predicted indications in this pack, which currently lack any clinical or literature evidence and should remain on Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.